BIOMARIN PHARMACEUTICAL INC

Form 4

February 10, 2015

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB 3235-0287 Number:

OMB APPROVAL

Expires:

January 31, 2005

0.5

Estimated average

5. Relationship of Reporting Person(s) to

burden hours per response...

if no longer subject to Section 16. Form 4 or Form 5 obligations

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. See Instruction

30(h) of the Investment Company Act of 1940

2. Issuer Name and Ticker or Trading

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person *

SPIEGELMAN DANIEL K			Symbol BIOMARIN PHARMACEUTICAL INC [BMRN]						Issuer (Check all applicable)			
(Last) (First) (Middle) 105 DIGITAL DRIVE		3. Date of Earliest Transaction (Month/Day/Year) 03/18/2013						Director 10% OwnerX Officer (give title Other (specify below) EVP, Chief Financial Officer				
	Filed(Month/Day/Year)				Aj	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting						
NOVATO,	CA 94949							Pe	Person			
(City)	(State)	(Zip)	Tab	ole I - No	n-D	erivative S	Securi	ties Acquir	ed, Disposed of, o	or Beneficially	y Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deeme Execution any (Month/Da	Date, if	Date, if Transaction or Disposed of (D) Code (Instr. 3, 4 and 5) y/Year) (Instr. 8) (A) or		(D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
Common Stock	03/18/2013	03/18/20	13	A(1)		7	A	\$ 61.4829	68,683	D		
Common Stock	03/18/2013	03/18/20	13	A(1)		7	A	\$ 61.3814	68,690	D		
Common Stock	03/20/2013	03/20/20	13	A(1)		5	A	\$ 61.988	68,695	D		
Common Stock	03/20/2013	03/20/20	13	A(1)		4	A	\$ 61.4325	68,699	D		
Common Stock	06/19/2013	06/19/20	13	A(1)		9	A	\$ 58.5678	68,708	D		

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

Commo Stock	n 06/19/2013	06/19/2013	A <u>(1)</u>	9	A	\$ 58.8478	68,717	D
Commo Stock	n 09/10/2013	09/10/2013	A <u>(1)</u>	8	A	\$ 70.0583	68,725	D
Commo Stock	n 09/10/2013	09/10/2013	A <u>(1)</u>	7	A	\$ 70.3029	68,732	D
Commo Stock	n 10/04/2013	10/04/2013	A <u>(1)</u>	5	A	\$ 74.074	68,737	D
Commo Stock	n 10/07/2013	10/07/2013	A <u>(1)</u>	6	A	\$ 74.8383	68,743	D
Commo Stock	n 10/30/2013	10/30/2013	A <u>(1)</u>	4	A	\$ 66.475	68,747	D
Commo Stock	n 10/30/2013	10/30/2013	A <u>(1)</u>	5	A	\$ 65.75	68,752	D
Commo Stock	n 11/20/2013	11/20/2013	A <u>(1)</u>	8	A	\$ 65.8863	68,760	D
Commo Stock	n 03/05/2014	03/05/2014	S(1)(2)	12	D	\$ 82.9258	68,748	D
Commo Stock	n 05/02/2014	05/02/2014	S(1)	3	D	\$ 58.0233	68,745	D
Commo Stock	n 05/02/2014	05/02/2014	S(1)	8	D	\$ 58.78	68,737	D
Commo Stock	n 08/06/2014	08/06/2014	A <u>(1)</u>	7	A	\$ 62.1671	68,744	D
Commo Stock	n 08/06/2014	08/06/2014	A <u>(1)</u>	7	A	\$ 62.1771	68,751	D
Commo Stock	n 09/03/2014	09/03/2014	S(1)(2)	9	D	\$ 69.8289	68,742	D
Commo Stock	n 09/03/2014	09/03/2014	S(1)(2)	9	D	\$ 69.7011	68,733	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5.	6. Date Exercisable and	7. Title and	8. Price of	9. Nu
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transactio	orNumber	Expiration Date	Amount of	Derivative	Deriv
Security	or Exercise		any	Code	of	(Month/Day/Year)	Underlying	Security	Secui
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Derivativo	e	Securities	(Instr. 5)	Bene

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

Derivative Securities (Instr. 3 and 4)
Security Acquired

Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)

Code V (A) (D) Date Expiration Title Amount

Exercisable Date

or Number of Shares Own

Follo

Repo

Trans

(Insti

Reporting Owners

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

SPIEGELMAN DANIEL K 105 DIGITAL DRIVE NOVATO, CA 94949

EVP, Chief Financial Officer

Signatures

/s/ Laura Randall Woodhead,
Attorney-in-Fact
02/10/2015

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Inadvertent transaction not directed by the reporting person through a broker-administered investment pool.
- Some of the transactions executed as reported herein resulted in a short swing profit under Section 16(b) of the Securities Exchange Act of 1934, as amended ("Section 16(b)"). The Reporting Person has made arrangements with the Issuer to disgorge short swing profits realized to the Issuer, and upon settlement, the Reporting Person will have discharged in full any obligation under Section 16(b) with respect to the reported transactions.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 3